MedTrace Logo

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

NCT03362437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-03-14

No results posted yet for this study

Summary

Assess the pharmacokinetics (fasting and fed), safety, and tolerability of BMS-986177 following oral dosing of Form A and Form B

Conditions

Interventions

DRUG

BMS-986177

Form A

DRUG

BMS-986177

Form B

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Briston-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-15
Primary Completion
2017-12-28
Completion
2017-12-28
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362437 on ClinicalTrials.gov